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Endothelins
Myocardial Actions of a New Class of Cytokines
Bernhard K. Kramer, MD; Masashi Nishida, MD, PhD;
Ralph A. Kelly, MD; and Thomas W. Smith, MD
It has long been assumed that the primary influ-
ences regulating cardiac contractility are the
extent of mechanical loading of muscle fibers
and the activity of the autonomic nervous system.
However, the vascular endothelium within the large
epicardial and penetrating coronary arteries is well
known to release vasodilator and vasoconstrictor
agents that regulate coronary blood flow and, by this
mechanism, indirectly affect cardiac contractility. In
response to a number of hormonal, metabolic, and
mechanical stimuli, vascular endothelium of the cor-
onary arteries has been shown to synthesize and
secrete compounds of disparate biological activity,
including mitogens, prothrombogens, antithrombo-
gens, and vasoactive substances. However, there is
growing evidence that locally elaborated paracrine
factors, perhaps derived from the microvascular en-
dothelium or the endocardium, also are important in
modifying cardiac function. Within the heart, the role
of the endocardial endothelium in normal cardiac
physiology has been examined in recent reports by
Brutsaert and colleagues1l2 documenting that in vitro
this endothelium regulates the inotropic response of
subjacent cardiac myofibrils to changes in extracellu-
lar Ca'4.
Among the biologically active autocoids released
by vascular endothelium are a recently described
group of peptide autocoids or cytokines known as
endothelins. Vascular endothelial cells have been
known since the mid 1980s to elaborate a vasocon-
strictor activity, as well as vasodilators such as endo-
thelium-derived relaxing factor and prostacyclins.3-6
However, it was not until 1988 that Yanagisawa and
colleagues,7 working in Tomoh Masaki's laboratory,
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reported the isolation of a potent 21-amino acid
vasoconstrictor peptide from the supernatant of cul-
tured porcine endothelial cells, which they termed
"endothelin." At least three isoforms of endothelin
have since been described, each with 21 amino acids
and four cysteine residues forming two disulfide
bonds (Figure 1).8 In addition to the three isoforms
of endothelin described by Masaki and colleagues, a
peptide autocoid recently identified in the murine
intestinal tract termed vasoactive intestinal contrac-
tor (VIC) differs from endothelin-2 by a single amino
acid substitution.9-11 Although VIC may possibly
represent a fourth isoform, a recent report suggests
that VIC is the murine (and rat) form of endothelin-2
because of the identical sizes of the human and rat
mRNAs for the precursor form of endothelin-2
known as preproendothelin-2, which differ markedly
from the larger mRNAs for preproendothelin-1 and
preproendothelin-3.12 The different endothelin iso-
forms are presumed to have arisen from a common
ancestor initially by exon duplication followed by
gene duplication with dispersion of the three known
isoform genes among three different chromosomes
(at least in humans). Interestingly, the venom of the
burrowing asp Atractaspis engaddensis contains pep-
tides termed "sarafotoxins" that were identified co-
incidently with the original description of endothe-
lin-1 and were noted to have remarkable homology to
the endothelins (Figure 1).13
Since the original description of endothelin, it has
been found to be a nearly ubiquitous peptide auto-
coid released from many endothelial cells, including
porcine aortic,4'14-17 bovine pulmonary,18 bovine ca-
rotid,19'20 bovine adrenal cortical capillary,2' and hu-
man umbilical vein22 and human mesenteric artery23
endothelial cells. Endothelin has also been identified
in numerous nonendothelial tissue sources, including
several renal cell lines,2425 canine airway epithelial
cells,26 and rabbit endometrial cells in primary cul-
ture.27 Using immunohistochemical and in situ hy-
bridization techniques, it has also been found in
relatively high levels in the central and peripheral
nervous systems, where its role has yet to be deter-
mined. In addition to their paracrine actions, endo-
thelins may also act as autocrine peptide regulatory
factors, as in the recent description of endothelin-l's
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FIGURE 1. Illustration of amino acid sequences of endothe-
lin-1, endothelin-2, vasoactive intestinal constrictor (VIC,
possibly the murine/rat analogue of endothelin-2), and endo-
thelin-3, as well as one ofthepeptide constituents ofthe venom
of the burrowing asp Atractaspis engaddensis, termed sarafo-
toxins, which, along with other members of this peptide family,
have a remarkable degree of homology to the endothelins.
Specific toxin illustrated is sarafotoxin S6b.
action in normal parathyroid tissue31 in a number of
transformed cell lines28-30 and in normal parathyroid
tissue.31
Given the widespread distribution of endothelins
throughout many different tissues, their expression
during ontogeny and into adult life, their primary
role as intercellular signaling factors, and the appar-
ent complexity of their effects including promoting
proliferation or cellular hypertrophy, the appellation
"cytokine" is appropriate to describe this class of
autocrine/paracrine peptide signaling factors. As re-
cently reviewed by Nathan and Sporn,32 most cyto-
kines arise from apparently unrelated cell types with
often unpredictable effects on an untested tissue or
cell type. They argue that the actions of cytokines on
a given cell at a given point in development is
determined largely by the context, including the
specific cell type involved, the composition of the
extracellular matrix, and the mix of other peptide
regulatory factors also present in the intercellular
milieu, several of which may have partially redundant
actions.32 Although not included in their review, the
local myocardial and intravascular release of endo-
thelins, and perhaps also of angiotensins, qualifies
both classes of peptides as cytokines as well. An
important conclusion drawn by Nathan and Sporn,
based on their argument that the actions of cytokines
(i.e., interleukins, interferons, colony-stimulating fac-
tors, peptide growth factors- and perhaps endothe-
lins and angiotensins) are "contextual," is that much
of the work examining the effects of a specific cyto-
kine on individual cells or isolated cell populations in
vitro may be misleading, "leading to the description
of countless, often contradictory bioactivities."32 Al-
though ultimately the physiological or pathophys-
iological role of a given cytokine must be determined
in the intact organism, possibly by using soluble
cytokine receptor complexes, specific receptor antag-
onists, or other techniques, in vitro modeling of
cytokine effects must address the biological complex-
ity of the relevant intercellular milieu. Although most
of the work that we and others have done on the
intramyocardial actions of endothelins has concen-
trated on primary cultures of neonatal myocytes or
on individual adult ventricular myocytes, in vitro
systems are being developed that more accurately
model the context of endothelin's actions, including
primary cocultures of cardiac myocytes with selected
nonmyocyte cells such as microvascular endothelium
and the use of extracellular matrixes that more
closely reflect those found in the cardiac interstitium.
Coronary Flow, Endothelial Cells, and
Myocardial Function
Shortly after endothelin had been identified as an
endothelium-derived vasoconstrictor, Masaki and col-
leagues33 also reported that endothelin-1 had a potent
inotropic activity in guinea pig atrial strips. Subse-
quently, high-affinity receptors were identified in mam-
malian atria and ventricles,34-36 and endothelin was
also found to act as a potent secretagogue for atrial
natriuretic peptide.37-43 A number of laboratories have
now confirmed these original reports, documenting
endothelin to be one of the most potent inotropic
agents yet described in mammalian myocardium.
The relevant site of origin of intracardiac endo-
thelins is unknown. However, the work of Brutsaert
and colleagues44"45 suggests that release of endothelin
or other cardiotropic autocoids by the endocardial
endothelium may be of physiological or pathophys-
iological importance in the regulation of myocardial
function. In addition, several lines of evidence point
to an appreciable role for coronary artery endothe-
lium, including microvascular endothelium, in modi-
fying cardiac contractile state. For example, the
importance of coronary flow rate per se as a deter-
minant of cardiac contractile state was originally
identified by the cardiac physiologist Gregg, as de-
tailed in a comprehensive review by Feigl.46 This
concept has since been a source of conti
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troversy.4748 By carefully demonstrating that the re-
lation between coronary flow rates and cardiac con-
tractility was not due to relative myocardial ischemia
at low flow rates and that there was no evidence for
increased sarcomere length at high flow rates (the
"garden hose" effect), Kitakaze and Marban48 re-
cently excluded two trivial explanations often raised
to explain the somewhat counterintuitive notion that
changing coronary flow rate per se modifies cardiac
contractile state. One remaining explanation is the
possibility that the coronary microvasculature senses
the changes in flow rate and releases paracrine-acting
mediators that alter the contractile state of the
myocardium.
Further evidence for the possible control of myo-
cardial function by endothelium has come from phar-
macological studies of peptide cytokines and other
autocoids of presumed endothelial origin such as
angiotensin II and endothelin. The role of angioten-
sin II in modifying cardiac function is being reexam-
ined with the recent detection by biochemical, immu-
nological, and in situ molecular biology techniques of
components of the renin-angiotensin system within
the heart (i.e., renin, angiotensinogen, and both
angiotensin converting enzyme (ACE) and the re-
cently described angiotensin I-specific, neutral serine
protease49). At present, however, the role of the
intracardiac renin-angiotensin system in normal and
abnormal physiology remains unclear.50
Evidence from in vitro studies indicates that tran-
scriptional regulation of preproendothelin messenger
RNA may occur by a dynamic interaction between
cardiac myocytes and adjacent endothelial cells. In
preliminary data from this laboratory, preproendo-
thelin mRNA was markedly induced in vitro in isolated
primary cultures of microvascular endothelial cells,
isolated from adult rat myocardium only when these
cells were cocultured with adult rat ventricular myo-
cytes (n=3). This differs from the constitutive produc-
tion of preproendothelin mRNA observed in large-
vessel (bovine aortic) endothelial cells.51 In contrast, no
preproendothelin mRNA was detected in cardiac mi-
crovascular endothelial cells cultured alone (i.e., in
monoculture) under similar conditions, although car-
diac myocyte-conditioned media could increase endo-
thelin precursor mRNA in monocultures of these mi-
crovascular endothelial cells.
Mechanism of Positive Inotropic Effect
of Endothelin-1
The positive inotropic effect of endothelin has
been documented in isolated hearts,52,53 in isolated
cardiac muscle preparations,3354-62 and in isolated
adult rat and rabbit ventricular cells.63,64 As with the
vasoconstrictor effects of the peptide, calcium chan-
nel blockers shift the dose-response curve to the
right, and a variety of other neurohumoral and
autocoid antagonists have no effect.33 63 Similarly, the
kinetics of endothelin-l's action on heart muscle
resemble those in vascular smooth muscle, with a
delayed onset of action and a maximal effect at 5-8
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FIGURE 2. Graph shows values for contractile amplitude
and peak systolic intracellular calcium activity [Ca2+]i given
for six cells loaded with the Ca2'-selective fluorescent probe
fura-2. Cells were initially exposed to 0. 9 mM external Ca'2 in
physiological buffer and were then gradually stepped down in
five successive increments to 0.1 mM Ca2+ followed by a
stepwise return back up to 0.9 mM extracellular Ca2', with
sufficient time at each step to allow contractile amplitude and
[Ca2+] to stabilize. Cells were exposed to this protocol in the
absence (open circles) or presence (closed circles) of 100pM
endothelin-1. Note that for any given level of systolic [Ca2"j,
expressed as a percentage of initial control values for systolic
[Ca2+]i at 0.9 mM Ca2, outside, contractile amplitude was
always higher in endothelin-treated cells. (From Reference 63,
with permission.)
minutes in isolated cell preparations. The positive
inotropic effect is quite prolonged, lasting 5-15 min-
utes after washout of the peptide.
In addition to the high potency, delayed onset of
action, and prolonged inotropic effect of endothelin
noted above, there is another unusual characteristic
of endothelin's mechanism of action as a positive
inotropic agent. We reported that in isolated adult
rat ventricular myocytes paced at 1.5 Hz, endothe-
lin-1 at concentrations below 1 nM yielded a maximal
inotropic response of about 100% above baseline.63
However, despite this appreciable increase in con-
tractile amplitude, we could not detect an increase in
cytosolic calcium as reported by fluorescence ratio
measurements by using the calcium-specific intracel-
lular probe fura-2.63 Endothelin thus appeared to be
acting to sensitize the myofilaments to calcium, at
least in isolated adult rat ventricular myocytes. In
contrast, Lauer et a164 did find an increase in calcium
transients and transmembrane calcium current in
isolated rabbit cells at 20 nM endothelin, although
contractility was not measured. We also noted a
variable increase in cytosolic calcium in isolated rat
cardiocytes at concentrations of endothelin in the
10-100 nM range, but this was well above the con-
centration eliciting a maximal inotropic effect of the
peptide (i.e., 0.5-1.0 nM).63 As shown in Figure 2,
when the calcium concentration of the buffer super-
fusing isolated single fura-2-loaded myocytes paced
at 1.5 Hz was varied from 0.1 to 0.9 mM Ca21 outside,
100 pM endothelin increased contractile amplitude
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FIGURE 3. Plot depicts time course of changes in pHi and
contractile amplitude with endothelin. Freshly isolated ventric-
ular myocytes superfused with physiological buffer atpH 7.4,
loaded with the pH-sensitive dye 2', 7'-bis(2-carboxyethyl)-5,6-
carboxyfluescein (BCECF) and stimulated at 1.5 Hz, were
exposed to 100 pM endothelin-1 at time 0. A change in
contractile amplitude (open symbols) orpHi (closed symbols)
was not apparent for about 4 minutes (p<O.05 at 4 minutes;
n=6), with a maximal effect at 7 minutes. (From Reference
72, with permission.)
with little or no change in the systolic level of Ca2+
transients as monitored concurrently in each paced
myocyte by changes in the fura-2 fluorescence ratio.63
Prior exposure of isolated myocytes to pertussis
toxin completely abolished the positive inotropic
effect of the peptide,63 implicating either a Go or Gi
GTP binding protein in the signal transduction steps
after endothelin's binding to its sarcolemmal recep-
tor. The intermediary role of GTP-binding proteins is
reflected in the deduced amino acid sequences of the
three endothelin receptors cloned to date.65-67
In contrast to our findings in freshly isolated adult
rat ventricular myocytes, pertussis toxin had no effect
on the endothelin-induced rise in inositol trisphos-
phate (EC50, 10 nM) in isolated adult rat atrial
myocytes.68 Significant stimulation of phospholipase
C resulting in phosphoinositide hydrolysis, by either
pertussis toxin- or cholera toxin-sensitive mecha-
nisms, has been documented as well in neonatal
ventricular myocytes, but again using concentrations
of endothelins and sarafotoxins (1 ,uM) well above
that which resulted in maximal increases in contrac-
tility in isolated adult ventricular myocytes.69
A rise in intracellular pH (pHi) has been well
documented to increase contractile amplitude with
little or no change in [Ca2+]170,71; therefore, we also
investigated whether this apparent sensitization of
the myofilaments to intracellular calcium with endo-
thelin could be attributed to a rise in pHi. As shown
in Figure 3, 100 pM endothelin increased pHi by
0.07±0.02 units (n=8) and contractile amplitude to
190+26% of baseline, whereas 1 nM endothelin
increased pHi by 0.13-+±0.03 units with little further
increase in contractility.72 Amiloride, an inhibitor of
sarcolemmal Na+-H+ exchange that had no effect on
baseline contractile amplitude in isolated adult rat
myocytes, completely prevented the intracellular al-
kalinization response to endothelin and blunted the
inotropic effect. Nonspecific inhibitors of protein
kinase C, such as H-7 and sphingosine, also dimin-
ished or abolished the rise in pHi with endothelin.72
However, neither amiloride nor inhibitors of protein
kinase C could completely suppress the positive
inotropic response. Conversely, pretreatment with
pertussis toxin, which as mentioned above had been
documented to abolish the inotropic response to
endothelin,63 only partially diminished the intracel-
lular alkalinization in isolated myocytes in response
to endothelin-1.72 Intracellular alkalinization as a
consequence of stimulation of the sarcolemmal
Na+-H+ antiporter has also been implicated recently
in the positive inotropic action of the a-adrenergic
agonist phenylephrine. As in the case of endothelin,
an amiloride congener reduced the maximal phenyl-
ephrine-mediated increase in myocardial contractil-
ity by about 50%.73
Endothelin's Role in Cardiac Myocyte Cell Biology
and Function
Intracellular alkalinization could also have other
roles in normal myocyte physiology aside from the
effects on contractility described above. A rise in pHi
is clearly associated with a mitogenic response in
many cells and with hypertrophy in vascular smooth
muscle.74-78 In addition, endothelin has been shown
to have mitogenic effects in vascular smooth muscle
cells79 as well as in other cell types.80-84 Importantly,
the mitogenic effects of endothelin and its effects on
the expression of certain proto-oncogenes such as
c-fos and c-jun, both of which are associated with
some forms of hypertrophic growth in cardiac myo-
cytes,85 occur at relatively low concentrations of
endothelin (i.e., <1 nM), concentrations that also
result in maximal increases in contractile amplitude
and pHi in isolated adult rat ventricular myocytes.63,72
Shubeita et a186 have recently demonstrated that
endothelin can cause hypertrophy directly in serum-
starved neonatal rat ventricular myocytes, as deter-
mined by increases in cell size and by the assembly of
myosin light chain-2 and other myofibrillar proteins.
This is accompanied by the activation of "immediate
early" gene expression (e.g., c-fos and erg-1) and by
the expression of atrial natriuretic peptide, with a
maximal response at 1 nM.86 Activation of phospho-
lipase C by endothelin has been well documented in
both established cell lines and primary cultures of
vascular smooth muscle cells,87 endothelial cells,81
and glial cells.88
The response of a variety of cell lines and primary
cultures pretreated with pertussis toxin and then
exposed to endothelin also implicates complex and
perhaps tissue-specific signal transduction mecha-
nisms for this peptide, comprising several indepen-
dently regulated pathways. A dissociation between
phospholipase C and phospholipase A2 activation in
vascular smooth muscle cells after endothelin admin-
istration has been noted, based on their response to
pertussis toxin and phorbol esters.89 As noted above
for atrial and neonatal rat myocytes, however, these
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effects have been observed only at higher concentra-
tions, typically with an EC 0 of 10 nM or higher; for
example, a large increase in phospholipase A2 acti-
vation with endothelin was seen in mesangial cells,
but only at concentrations near 0.1 ,uM.83 However,
Shubeita et a186 have demonstrated in neonatal rat
myocyte cultures maximal production of diacylglyc-
erol and phosphoinositides at 10 nM with an EC50 of
about 0.5 nM.
Although it is quite possible that different actions
of the endothelin peptides on ventricular myocytes
may be manifest at concentrations below and above 1
nM, it is unknown what local tissue concentrations of
endothelin are relevant. The reported Kd for receptor
binding of endothelin-1 in cardiac tissue is in the
subnanomolar range,34-36 but higher concentrations
could occur locally, especially under pathological
conditions. Interestingly, plasma endothelin levels
were found to double in dogs with congestive heart
failure induced by rapid ventricular pacing.90 It is
unclear whether the elevated plasma levels of endo-
thelin-1 were contributing to an elevated systemic
vascular resistance or simply reflecting the activation
of a number of neurohumoral and paracrine regula-
tory systems in advanced heart failure. The answers
to these questions will require the development of
specific receptor antagonists. Nevertheless, the data
reported by Shubeita et a186 and evidence from our
own laboratory63'72 indicate that endothelin, in
amounts well below 1 nM, will result in increased
contractile function and an intracellular alkaliniza-
tion coupled with increased transcription of selected
genes that could facilitate the development of myo-
cyte hypertrophy.
Summary
There is growing evidence to support the existence of
a dynamic interaction in vivo between cardiac myocytes
and adjacent microvascular endothelial cells in the
regulation of both cardiac myocyte and possibly endo-
thelial cell phenotype and function. Endothelins may
be only one of several endogenous cytokines or auto-
coids that are released by the cardiac microvascular
and/or endocardial endothelium and transported vec-
torially to adjacent myocytes that could modify cardiac
contractile state, perhaps in response to changes in
microvascular blood flow. Similarly, cardiac myocytes
themselves could release cytokines that could directly
affect endothelial cell proliferation or angiogenesis and
indirectly elicit or modify the release of endothelium-
derived cytokines and autocoids. Thus, in addition to
modifying function, endothelial cell-cardiac myocyte
interactions may also be of importance in the dynamic
events that lead to myocardial wall remodeling and
angiogenesis during hypertrophic growth and in the
response to cardiac injury.
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